A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
Eligible age
18+ yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to learn if AT673 contributes to additional weight loss and glycemic control when given with semaglutide in participants with overweight/obesity and type 2 diabetes. The main questions it aims to answer are: * To compare the effect on body weight of two doses of AT673 once-weekly versus matched placebo when concurrently administered with semaglutide once-weekly * To evaluate the effect of AT673 on glycated hemoglobin (HbA1c) * To compare the safety and tolerability of AT673 versus matched placebo when concurrently administered with semaglutide
Sponsor: Antag Therapeutics
You may qualify if…
- ✓ 1. Signed informed consent prior to start the Screening Visit procedures.
- ✓ 2. Female and male participants ≥18 years of age at time of consent
- ✓ 3. BMI g ≥27.0 kg/m2 at screening.
- ✓ 4. HbA1c ≥7 and ≤10% (53-86 mmol/mol) at screening.
- ✓ 5. Diagnosis of type 2 diabetes mellitus for ≥ 180 days prior to screening.
- ✓ 6. Either treated with diet and exercise alone or on stable (at least 90 days prior to screening) treatment with metformin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, sulfonylurea, and/or DPP4 inhibitor as monotherapy or combination therapy, per approved local label.
- ✓ a) Note: Participants treated with sulfonylureas and/or DPP4 inhibitors must discontinue these at least 24 hours prior to initiation of semaglutide.
- ✓ 7. Participant has had at least 1 unsuccessful attempt at weight loss by diet and exercise in the opinion of the investigator.
You may not qualify if…
- ✕ 1. Participant has had gastric bypass or other bariatric surgery or endoscopic procedure or any metabolic procedures (e.g. duodenal resurfacing, intragastric balloon, etc.) except for the following:
- ✕ 1. Liposuction and/or abdominoplasty that was performed \> 1 year before screening
- ✕ 2. Laparoscopic gastric band that was removed \> 1 year before screening
- ✕ 3. Intragastric balloon that was removed \> 1 year before screening
- ✕ 4. Duodenal-jejunal bypass sleeve that was removed \> 1 year before screening.
- ✕ 2. Participant has had a self-reported or medically recorded change in body weight \> 5% within 3 months of screening OR has recorded change in body weight \>3% between screening and randomization.
- ✕ 3. Participant is currently using insulin or used insulin within 3 months before screening.
- ✕ 4. Participant is currently using sulfonylureas and/or DPP4 inhibitors and is unable or unwilling to discontinue the use of these medications at least 24 hours prior to initiation of semaglutide.
Where it's recruiting
Chandler
Anaheim
Hollywood · Tampa
Atlanta · Decatur · Savannah
Salt Lake City
Source: ClinicalTrials.gov · NCT07724340 · last updated 2026-07-24